OUR AI PLATFORM
Science behind
the scene
Driven by biology. Powered by AI.
![](data:image/svg+xml,<svg display="block" id="81247265" role="presentation" viewBox="0 0 124 62" xmlns="http://www.w3.org/2000/svg"><path d="M 0 30.5 C 0 13.655 13.655 0 30.5 0 C 47.345 0 61 13.655 61 30.5 C 61 47.345 47.345 61 30.5 61 C 13.655 61 0 47.345 0 30.5 Z" fill="transparent" height="61px" id="dwfJwd65B" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgba(21, 108, 194, 0.14)" transform="translate(62.5 0.5)" width="61px"/><path d="M 9.096 6.433 L 5.375 0 C 3.742 0.941 2.385 2.295 1.442 3.927 C 0.498 5.558 0.001 7.41 0 9.295 L 7.442 9.295 C 7.443 8.715 7.596 8.145 7.886 7.643 C 8.177 7.14 8.594 6.724 9.096 6.433 Z" fill="transparent" height="9.294599999999999px" id="Xepx22RJ3" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(21, 108, 194)" transform="translate(82 21)" width="9.096199999999996px"/><path d="M 1.654 9.295 L 9.096 9.295 C 9.095 7.41 8.598 5.558 7.654 3.927 C 6.711 2.295 5.354 0.941 3.721 0 L 0 6.433 C 0.502 6.724 0.92 7.14 1.21 7.643 C 1.5 8.145 1.653 8.715 1.654 9.295 Z" fill="transparent" height="9.294599999999999px" id="XLUpjx1EX" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(21, 108, 194)" transform="translate(94.404 21)" width="9.096199999999996px"/><path d="M 5.375 0.43 C 4.796 0.434 4.225 0.286 3.721 0 L 0 6.434 C 1.635 7.375 3.488 7.871 5.375 7.871 C 7.262 7.871 9.115 7.375 10.75 6.434 L 7.029 0 C 6.525 0.286 5.954 0.434 5.375 0.43 Z" fill="transparent" height="7.871200000000002px" id="WQmiun3t0" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(21, 108, 194)" transform="translate(87.375 33.172)" width="10.75px"/></svg>)
Traditional Approach
Predict PK, PD & biodistribution
Preclinical development
Clinical trials begin
Toxicity discovered late
Identify organ & cell-type risk
Optimize candidate before clinic
Enter clinic with greater confidence
3-5 Years
$5-$10M
Up to 100x
Up to 65x
lower cost
faster
to reach preclinical
4-6 Weeks
Up to $100K
to reach preclinical
Problem Solved
Faster, cheaper, and more precise
Traditional development can take years and millions of dollars before major safety risks become visible. Epitorix predicts biodistribution, organ risk, and cell-type risk earlier, enabling faster and lower-cost candidate optimization before clinical trials.
Traditional
mRNA/Phage Display
AI Structure-Guided
Generation
Targeted candidate generation
Traditional mRNA/phage display creates noisy, non-site-specific libraries and can take months. Epitorix generates ~10,000 high-quality site- and target-specific candidates with far less biological noise.
~6 Months Saved to Generate High Quality Candidate
~60% Success Rate Increase
Higher accuracy and target specificity
Off-target
proteome-wide off-target prediction
Traditional microarrays are limited by protein coverage, biological noise, cost, and long timelines. Epitorix predicts protein off-targets for targets, small molecules, and peptides in about 1 hour with >90% accuracy.
Traditional methods: expensive and limited number of panels
Epitorix: proteome-scale in ~1 hour
Highly Accurate Off-Target Prediction
In retrospective analyses, our model achieved over 90% accuracy in detecting known off-target interactions.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path d="M 15.75 0 L 5.25 10.5 L 0 5.25" fill="transparent" height="10.5px" id="Yf1dOOlOm" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.4" stroke="rgb(65, 23, 94)" transform="translate(4.5 6.75)" width="15.75px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><g d="M 0 24 L 0 0 L 24 0 L 24 24 Z M 12 3.001 L 12 6.001 M 21.002 11.999 L 18.002 11.999 M 18.364 18.364 L 16.242 16.242 M 11.998 21.001 L 11.998 18.001 M 5.636 18.366 L 7.757 16.244 M 3 12 L 6 12 M 5.636 5.637 L 7.757 7.758" fill="transparent" height="24px" id="B6dzfyK_U" width="24px"><path d="M 0 24 L 0 0 L 24 0 L 24 24 Z" fill="transparent" height="24px" id="p7qz8Zisl" width="24px"/><path d="M 0 0 L 0 3" fill="transparent" height="2.9999999999999996px" id="NFz6Orc3D" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(12 3.001)" width="1px"/><path d="M 3 0 L 0 0" fill="transparent" height="1px" id="lLDXK6JMr" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(18.002 11.999)" width="3px"/><path d="M 2.121 2.121 L 0 0" fill="transparent" height="2.121490909090909px" id="huwUTlX5U" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(16.242 16.242)" width="2.1214909090909195px"/><path d="M 0 3 L 0 0" fill="transparent" height="3px" id="WZRX2MJ_1" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(11.998 18.001)" width="1px"/><path d="M 0 2.122 L 2.122 0" fill="transparent" height="2.121600000000001px" id="u0uaqzcoG" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(5.636 16.244)" width="2.1215563636363663px"/><path d="M 0 0 L 3 0" fill="transparent" height="1px" id="xIy8IcILu" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(3 12)" width="3px"/><path d="M 0 0 L 2.122 2.122" fill="transparent" height="2.1215672727272725px" id="t_MfJqWZA" stroke-dasharray="" stroke-linecap="round" stroke-linejoin="round" stroke-width="2.18" stroke="rgb(65, 23, 94)" transform="translate(5.636 5.637)" width="2.1215563636363663px"/></g></svg>)
F1 · Binder
R · Peptide
R · Small-Molecule
Ranking
Kd evaluation at scale
SPR and BLI require synthesis and wet-lab testing and can take months. Molecular dynamic and FEP+ need multiple hours per prediction.
Epitorix predicts Kd at scale:
Pearson R = 0.70 for small molecules and 0.84 for peptides, screening thousands in minutes.
High speed ranking at ~1,000 molecules/s
Comparable accuracy to costly computational methods.
Biodistribution and organ/cell at risk
Predict side-effects before trials
Traditional programs often discover toxicity only after clinical testing begins. Epitorix predicts PK, PD, biodistribution, cell-type risk, and organ risk to optimize radiotherapeutics before side effects
emerge.
Earlier safety insight
Optimize before the clinic
Kidney
Risk
Risk
Risk
Risk
Liver
Kidney proximal
tubular cells
High
Moderate
Moderate
Low
Liver sinusoidal cells
Hematopoietic stem & progenitor cells
Salivary acinar cells
Marrow
Salviary
PharmPhax
A Reliable System to De-Risk Radiopharmaceutical Industrial Investment
We put certainty and intelligence at your fingertips
Clear Answers to YOUr Common Questions
/FAQ
What problem does Epitorix fundamentally address?
Radiopharmaceutical development is slow, expensive, and fragmented. Critical questions about target suitability, binding affinity, off-target interactions, biodistribution, organ exposure, and cell-specific toxicity are often evaluated through separate experimental workflows. Epitorix integrates these decisions into an AI-driven discovery and de-risking ecosystem designed to identify stronger candidates and potential development risks earlier.
What is EPiQ™?
Who owns molecules generated through EPiQ™?
Are EPiQ™-generated molecules guaranteed to be unique?
Is Epitorix intended for direct clinical decision-making?
What is PharmPhax™, and how does it de-risk radiopharmaceutical development?
How do I determine whether EPiQ™, PharmPhax™, EPITwin™, or Studio is right for me?